10-Q: Zomedica Corp. Reports First Quarter 2024 Results with Revenue Growth and Increased Net Loss

Zomedica Corp. saw a 14% increase in revenue in the first quarter of 2024 compared to the same period last year, but also experienced a larger net loss.

Summary

• Zomedica Corp. reported a net revenue of $6.262 million for the three months ended March 31, 2024, compared to $5.482 million for the same period in 2023, representing a 14% increase.
• The company's cost of revenue increased by 30% to $2.145 million, up from $1.647 million in the first quarter of 2023.
• Gross profit for the quarter was $4.117 million, with a gross profit margin of 66%, down from 70% in the same period last year.
• Operating expenses also increased, with general and administrative expenses rising by 23% to $8.625 million, research and development expenses increasing by 93% to $1.771 million, and selling and marketing expenses increasing by 20% to $4.107 million.
• The company reported a net loss of $9.160 million for the quarter, compared to a net loss of $6.385 million in the first quarter of 2023.
• The basic and diluted loss per share was $0.009, compared to $0.007 in the same period last year.
• Cash used in operating activities increased to $7.590 million, while cash provided by investing activities was $5.625 million.
• As of March 31, 2024, the company had cash and cash equivalents of $10.939 million and a working capital of $84.061 million.

Sentiment

Score: 4

Explanation: The document shows a mixed picture with revenue growth offset by increased losses and a material weakness in internal controls. The company is spending heavily on R&D and marketing, but it is not yet translating into profitability. The sentiment is cautiously negative due to the increased losses and control issues.

Positives

• Zomedica experienced a 14% increase in net revenue, indicating growth in sales.
• The company's existing cash is considered sufficient to fund short-term needs.
• The company has a working capital of $84.061 million.

Negatives

• The company's net loss increased by 43% year-over-year, reaching $9.160 million.
• Gross profit margin decreased from 70% to 66%, indicating increased costs relative to revenue.
• Cash used in operating activities increased by 78% year-over-year.
• The company has an accumulated deficit of $180.093 million.

Risks

• The company is experiencing ongoing losses and negative cash flows from operations.
• There is a material weakness in internal control over financial reporting related to the timeliness and precision of management's review controls around financial projections relevant to the evaluation of goodwill impairment.
• The company's future capital requirements depend on various factors, including the costs of development, commercialization, and manufacturing.
• The company is subject to risks related to adverse macroeconomic conditions, supply chain disruptions, and the ability to attract and retain key personnel.
• The company is exposed to potential impacts from climate change on its operations and supply chain.

Future Outlook

The company expects revenue to increase in subsequent periods as they increase sales, marketing, and commercialization efforts. They also anticipate that costs of revenue, research and development, and selling and marketing expenses will increase in line with product expansion and growth in commercialization efforts. The company expects to continue to record net losses until revenue from product sales offsets operating expenses.

Management Comments

• Management believes that existing cash is sufficient to fund short-term needs.
• Management is committed to maintaining a strong internal control environment and is developing a plan to remediate the material weakness.

Industry Context

Zomedica operates in the veterinary health industry, focusing on companion animal products. The company's performance is influenced by trends in pet ownership, veterinary spending, and technological advancements in diagnostics and therapeutics. The company is expanding its product offerings through acquisitions and internal development, which is a common strategy in the competitive veterinary health market.

Comparison to Industry Standards

• Zomedica's revenue growth of 14% is a positive sign, but the increased net loss and decreased gross profit margin are concerning when compared to industry peers.
• Companies like IDEXX Laboratories and Zoetis, which are established players in the animal health market, typically have higher gross profit margins and are profitable.
• Zomedica's increased spending on R&D is in line with industry trends, as innovation is crucial for growth in this sector, but the company needs to demonstrate a return on these investments.
• The material weakness in internal control over financial reporting is a significant concern and needs to be addressed to meet industry standards for financial transparency and reliability.
• The company's cash position is relatively low compared to larger competitors, which may limit its ability to pursue aggressive growth strategies or acquisitions.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the material weakness in internal controls.
• Employees may be impacted by the company's financial performance and any potential restructuring or cost-cutting measures.
• Customers may be affected by the company's ability to deliver products and services if financial challenges persist.
• Suppliers may be impacted by the company's ability to pay for goods and services if financial challenges persist.
• Creditors may be concerned about the company's ability to repay debts if financial challenges persist.

Next Steps

• The company plans to continue to develop and commercialize its products.
• The company will focus on remediating the material weakness in internal control over financial reporting.
• The company will continue to evaluate its business plans and strategy.

Key Dates

Keywords

Zomedica, veterinary health, diagnostics, therapeutics, financial results, revenue, net loss, gross profit, operating expenses, cash flow, internal control, stock options